CME/CE - PACE-CME

Episodes 81-96 of 102

Emerging Evidence in HF Care
Emerging Evidence in HF Care
MinuteCE®
Emerging Evidence in HF Care
1.25 program credits
- Pardeep Jhund, MD, PhD
- John McMurray, MD
1.25 program credits
MinuteCE®
Emerging perspectives in the diagnosis and management of hypertrophic cardiomyopathy
1.00 credit 3 episodes
- Perry Elliott, MD
- Aleš Linhart, MD, PhD
- Iacopo Olivotto, MD
1.00 credit 3 episodes
HCM: Understanding the condition
HCM: Understanding the condition
MinuteCE®
HCM: Understanding the condition
1.00 program credit
- Perry Elliott, MD
1.00 program credit
Diagnosing HCM: What a cardiologist needs to know
Diagnosing HCM: What a cardiologist needs to know
MinuteCE®
Diagnosing HCM: What a cardiologist needs to know
1.00 program credit
- Aleš Linhart, MD, PhD
1.00 program credit
Novel approaches in managing patients with HCM
Novel approaches in managing patients with HCM
MinuteCE®
Novel approaches in managing patients with HCM
1.00 program credit
- Iacopo Olivotto, MD
1.00 program credit
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
MinuteCE®
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
1.00 program credit
- Pam R. Taub, MD, FACC, FASPC
1.00 program credit
Perspectives on the results of recent clinical outcomes trials with EPA prevention
Perspectives on the results of recent clinical outcomes trials with EPA prevention
MinuteCE®
Perspectives on the results of recent clinical outcomes trials with EPA prevention
1.00 program credit
- P. Gabriel Steg, MD
1.00 program credit
Challenges in ASCVD reduction and TG-related risk
Challenges in ASCVD reduction and TG-related risk
MinuteCE®
Challenges in ASCVD reduction and TG-related risk
1.00 program credit
- Erik Stroes
1.00 program credit
MinuteCE®
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
1.00 credit 3 episodes
- Erik Stroes
- P. Gabriel Steg, MD
- Pam R. Taub, MD, FACC, FASPC
1.00 credit 3 episodes
MinuteCE®
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
1.00 credit 4 episodes
- Kausik Ray, MBChB, MD, MPhil
- Lale Tokgözoğlu, MD
- Prof. dr. Fabrice Martens
- Erin Michos
1.00 credit 4 episodes
The evolving need and challenges to reach LDL-c targets in high-risk patients
The evolving need and challenges to reach LDL-c targets in high-risk patients
MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program credit
- Kausik Ray, MBChB, MD, MPhil
1.00 program credit
Oral cholesterol-lowering therapies: The basis of prevention
Oral cholesterol-lowering therapies: The basis of prevention
MinuteCE®
Oral cholesterol-lowering therapies: The basis of prevention
1.00 program credit
- Lale Tokgözoğlu, MD
1.00 program credit
PCSK9i: Benefits across the spectrum of cardiovascular disease
PCSK9i: Benefits across the spectrum of cardiovascular disease
MinuteCE®
PCSK9i: Benefits across the spectrum of cardiovascular disease
1.00 program credit
- Prof. dr. Fabrice Martens
1.00 program credit
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program credit
- Erin Michos
1.00 program credit
MinuteCE®
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
1.00 credit 3 episodes
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Roxana Mehran, MD
1.00 credit 3 episodes
Unmet needs in lowering LDL-c
Unmet needs in lowering LDL-c
MinuteCE®
Unmet needs in lowering LDL-c
1.00 program credit
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
1.00 program credit

6/7